You need to be logged in to view this video
Angiogenesis As Breakthrough Therapy for the Treatment of Heart Disease, Peripheral Artery Disease (PAD), and Diabetic Foot Ulcers
Released on Sunday, June 16, 2019•BIOTECH
Learn about clinical trials were angiogenesis (the growth of new blood vessels in damaged tissues or organs) is utilized to stimulate the growth of healthy new blood vessels in a number of diseases with no current viable treatments, including no-option coronary artery disease, peripheral artery disease, and chronic, non-healing diabetic foot ulcers. See and learn how angiogenesis can succeed in being an effective treatment for these disorders.
Jack Jacobs
Zhittya Genesis Medicine, Inc.,
President and Chief Scientific Officer
Dr. Jack Jacobs has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations, as well as the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of biological chemistry at Merck and for 15 years worked with Mr. Daniel Montano as cardiovascular biotherapeutics' chief scientific officer. Dr. Jacobs oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers, and peripheral artery disease. He also oversaw the manufacturing of clinical lots of FGF-1 that were used in those clinical studies. Dr. Jacobs received a BS degree from Davidson College and a PhD in molecular biology from Washington University, St. Louis.
Trending Now
Filter By Category
Filter By Keywords
Loading...